Home/Filings/4/0001760460-21-000002
4//SEC Filing

Wang Theodore T 4

Accession 0001760460-21-000002

CIK 0001600132other

Filed

Apr 25, 8:00 PM ET

Accepted

Apr 26, 12:39 PM ET

Size

16.5 KB

Accession

0001760460-21-000002

Insider Transaction Report

Form 4
Period: 2021-04-26
Transactions
  • Award

    Common Stock

    2021-04-26$4.00/sh+609,231$2,436,9241,763,077 total
  • Award

    Warrants (Right to buy)

    2021-04-26+380,950380,950 total
    Exercise: $12.00From: 2016-11-29Exp: 2023-11-29Common Stock (380,950 underlying)
  • Award

    Warrants (Right to buy)

    2021-04-26+304,286685,236 total
    Exercise: $18.63From: 2018-03-29Exp: 2022-09-29Common Stock (304,286 underlying)
Transactions
  • Award

    Warrants (Right to buy)

    2021-04-26+304,286685,236 total
    Exercise: $18.63From: 2018-03-29Exp: 2022-09-29Common Stock (304,286 underlying)
  • Award

    Warrants (Right to buy)

    2021-04-26+380,950380,950 total
    Exercise: $12.00From: 2016-11-29Exp: 2023-11-29Common Stock (380,950 underlying)
  • Award

    Common Stock

    2021-04-26$4.00/sh+609,231$2,436,9241,763,077 total
Wang Theodore T
Director10% Owner
Transactions
  • Award

    Warrants (Right to buy)

    2021-04-26+380,950380,950 total
    Exercise: $12.00From: 2016-11-29Exp: 2023-11-29Common Stock (380,950 underlying)
  • Award

    Common Stock

    2021-04-26$4.00/sh+609,231$2,436,9241,763,077 total
  • Award

    Warrants (Right to buy)

    2021-04-26+304,286685,236 total
    Exercise: $18.63From: 2018-03-29Exp: 2022-09-29Common Stock (304,286 underlying)
Transactions
  • Award

    Warrants (Right to buy)

    2021-04-26+380,950380,950 total
    Exercise: $12.00From: 2016-11-29Exp: 2023-11-29Common Stock (380,950 underlying)
  • Award

    Common Stock

    2021-04-26$4.00/sh+609,231$2,436,9241,763,077 total
  • Award

    Warrants (Right to buy)

    2021-04-26+304,286685,236 total
    Exercise: $18.63From: 2018-03-29Exp: 2022-09-29Common Stock (304,286 underlying)
Transactions
  • Award

    Warrants (Right to buy)

    2021-04-26+304,286685,236 total
    Exercise: $18.63From: 2018-03-29Exp: 2022-09-29Common Stock (304,286 underlying)
  • Award

    Common Stock

    2021-04-26$4.00/sh+609,231$2,436,9241,763,077 total
  • Award

    Warrants (Right to buy)

    2021-04-26+380,950380,950 total
    Exercise: $12.00From: 2016-11-29Exp: 2023-11-29Common Stock (380,950 underlying)
Footnotes (1)
  • [F1]These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Issuer

Bellerophon Therapeutics, Inc.

CIK 0001600132

Entity typeother

Related Parties

1
  • filerCIK 0001694061

Filing Metadata

Form type
4
Filed
Apr 25, 8:00 PM ET
Accepted
Apr 26, 12:39 PM ET
Size
16.5 KB